NCT00636298View on ClinicalTrials.gov

Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2012

Conditions
Esophageal Carcinoma
Interventions
DRUG

Bevacizumab, cetuximab

"Cetuximab - 400 mg/m2 loading, then 250 mg/m2 weekly~Bevacizumab - 10 mg/kg every 2 weeks"

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Emory University

OTHER